Influence of patient, physician, and hospital characteristics on the receipt of guideline-concordant care for inflammatory breast cancer

被引:24
作者
Denu, Ryan A. [1 ]
Hampton, John M. [2 ]
Currey, Adam [3 ]
Anderson, Roger T. [4 ]
Cress, Rosemary D. [5 ]
Fleming, Steven T. [6 ]
Lipscomb, Joseph [7 ,8 ]
Sabatino, Susan A. [9 ]
Wu, Xiao-Cheng [10 ]
Wilson, J. Frank [3 ]
Trentham-Dietz, Amy [11 ]
机构
[1] Univ Wisconsin, Med Scientist Training Program, 6068 WIMR,1111 Highland Ave, Madison, WI 53705 USA
[2] Univ Wisconsin, Carbone Canc Ctr, 610 Walnut St,Room 307,WARF Bldg, Madison, WI 53726 USA
[3] Med Coll Wisconsin, Dept Radiat Oncol, 8701 W Watertown Plank Rd, Milwaukee, WI 53226 USA
[4] Penn State Univ, Div Hlth Serv Res, Coll Med, 500 Univ Dr, Hershey, PA 17033 USA
[5] Univ Calif Davis, Inst Publ Hlth, Canc Registry Greater Calif, Dept Publ Hlth Sci,Sch Med, One Shields Ave,Med Sci 1C, Davis, CA 95616 USA
[6] Univ Kentucky, Coll Publ Hlth, 111 Washington Ave, Lexington, KY 40536 USA
[7] Emory Univ, Rollins Sch Publ Hlth, 1518 Clifton Rd, Atlanta, GA 30322 USA
[8] Emory Univ, Winship Canc Inst, 1518 Clifton Rd, Atlanta, GA 30322 USA
[9] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30333 USA
[10] LSU, Hlth Sci Ctr, Sch Publ Hlth, 2020 Gravier St,3rd Floor, New Orleans, LA 70112 USA
[11] Univ Wisconsin, Dept Populat Hlth Sci, Carbone Canc Ctr, 610 Walnut St,Room 307,WARF Bldg, Madison, WI 53726 USA
关键词
Inflammatory breast cancer; Breast cancer; Guideline; Healthcare disparities; Epidemiology; INTERNATIONAL EXPERT PANEL; END RESULTS PROGRAM; CARCINOMA INCIDENCE; SURVIVAL; EPIDEMIOLOGY; SURVEILLANCE; OUTCOMES; THERAPY; CHEMOTHERAPY; RADIOTHERAPY;
D O I
10.1016/j.canep.2015.11.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Inflammatory breast cancer (IBC) is an aggressive subtype of breast cancer for which treatments vary, so we sought to identify factors that affect the receipt of guideline-concordant care. Methods: Patients diagnosed with IBC in 2004 were identified from the Breast and Prostate Cancer Data Quality and Patterns of Care Study, containing information from cancer registries in seven states. Variation in guideline-concordant care for IBC, based on National Comprehensive Cancer Network (NCCN) guidelines, was assessed according to patient, physician, and hospital characteristics. Results: Of the 107 IBC patients in the study without distant metastasis at the time of diagnosis, only 25.8% received treatment concordant with guidelines. Predictors of non-concordance included patient age (>= 70 years), non-white race, normal body mass index (BMI 18.5-25 kg/m(2)), patients with physicians graduating from medical school >15 years prior, and smaller hospital size (<200 beds). IBC patients survived longer if they received guideline-concordant treatment based on either 2003 (p = 0.06) or 2013 (p = 0.06) NCCN guidelines. Conclusions: Targeting factors associated with receipt of care that is not guideline-concordant may reduce survival disparities in IBC patients. Prompt referral for neoadjuvant chemotherapy and post-operative radiation therapy is also crucial. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:7 / 14
页数:8
相关论文
共 46 条
  • [1] Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0
  • [2] Anderson William F, 2005, Breast Dis, V22, P9
  • [3] Impact of surgeon and hospital volume on outcomes of radical prostatectomy
    Barocas, Daniel A.
    Mitchell, Robert
    Chang, Sam S.
    Cookson, Michael S.
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2010, 28 (03) : 243 - 250
  • [4] Racial and Socioeconomic Disparities in Adjuvant Chemotherapy for Older Women With Lymph Node-positive, Operable Breast Cancer
    Bhargava, Alessia
    Du, Xianglin L.
    [J]. CANCER, 2009, 115 (13) : 2999 - 3008
  • [5] Underuse of Breast Cancer Adjuvant Treatment: Patient Knowledge, Beliefs, and Medical Mistrust
    Bickell, Nina A.
    Weidmann, Jessica
    Fei, Kezhen
    Lin, Jenny J.
    Leventhal, Howard
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (31) : 5160 - 5167
  • [6] Molecular profiling of inflammatory breast cancer:: Identification of a poor-prognosis gene expression signature
    Bièche, I
    Lerebours, F
    Tozlu, S
    Espie, M
    Marty, M
    Lidereau, R
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (20) : 6789 - 6795
  • [7] INFLAMMATORY CARCINOMAS OF THE BREAST - A CLINICAL, PATHOLOGICAL, OR A CLINICAL AND PATHOLOGICAL DEFINITION
    BONNIER, P
    CHARPIN, C
    LEJEUNE, C
    ROMAIN, S
    TUBIANA, N
    BEEDASSY, B
    MARTIN, PM
    SERMENT, H
    PIANA, L
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1995, 62 (04) : 382 - 385
  • [8] Locoregional treatment outcomes after multimodality management of inflammatory breast cancer
    Bristol, Ian J.
    Woodward, Wendy A.
    Strom, Eric A.
    Cristofanilli, Massimo
    Domain, Delora
    Singletary, S. Eva
    Perkins, George H.
    Oh, Julia L.
    Yu, Tse-Kuan
    Terrefe, Welela
    Sahin, Aysegul A.
    Hunt, Kelly K.
    Hortobagyi, Gabriel N.
    Buchholz, Thomas A.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (02): : 474 - 484
  • [9] Inflammatory breast cancer and body mass index
    Chang, S
    Buzdar, AU
    Hursting, SD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (12) : 3731 - 3735
  • [10] Inflammatory breast cancer survival: The role of obesity and menopausal status at diagnosis
    Chang, S
    Alderfer, JR
    Asmar, L
    Buzdar, AU
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2000, 64 (02) : 157 - 163